Upstream Bio to present phase 2 VALIANT trial data on verekitug for severe asthma at ERS 2026

Traders Union
All News
Business & Wealth
Companies
Upstream Bio trials verekitug in asthma

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

08.09.2026

Upstream Bio to present phase 2 VALIANT trial data on verekitug for severe asthma at ERS 2026 — Upstream Bio trials verekitug in asthma

Upstream Bio has scheduled an oral presentation of its VALIANT phase 2 trial results at ERS 2026, focusing on the efficacy and safety of verekitug, a TSLP receptor antagonist, in treating severe asthma.

The presentation is set for September 8, 2026, from 9:30 to 9:35am CEST in session 3I.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Upstream Bio recently announced plans for pivotal Phase 3 trials of verekutug, as its stock traded at $6.62 following the news. The company has also appointed Marie Sanchirico, PhD, MBA, to lead Medical Affairs in an effort to strengthen relationships with medical experts and drive collaboration. These steps come as Upstream Bio prepares to present VALIANT phase 2 data at ERS 2026.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Upstream Bio

Editor's Picks for You

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

By Pavlo Kot
7 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Editors' Picks

China’s crypto paradox: A booming market despite the ban?

By Alena Volkova
13 hours ago

China’s crypto paradox: A booming market despite the ban?

Editors' Picks

Global Microsoft outage: What happened and how serious is it?

By Mikhail Vnuchkov
Yesterday

Global Microsoft outage: What happened and how serious is it?

Editors' Picks

All Editors' Top Picks

Latest Upstream Bio News

Upstream Bio advances verekirug initiatives in asthma, CRSwNP, and COPD following Q3 2026 earnings

By Eugene Komchuk
10.11.2026

Upstream Bio advances verekirug initiatives in asthma, CRSwNP, and COPD following Q3 2026 earnings

Companies

Upstream Bio announces pivotal Phase 3 plans for verekutug while stock edges lower

By Dmytro Kharkov
01.09.2026

Upstream Bio announces pivotal Phase 3 plans for verekutug while stock edges lower

Companies

Upstream Bio plans pivotal Phase 3 trials for verekitug in severe asthma and CRSwNP

By Igor Krasulya
01.09.2026

Upstream Bio plans pivotal Phase 3 trials for verekitug in severe asthma and CRSwNP

Companies

All Upstream Bio News

Pavlo Kot
7 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Alena Volkova
13 hours ago

China’s crypto paradox: A booming market despite the ban?

Mikhail Vnuchkov
Yesterday

Global Microsoft outage: What happened and how serious is it?

Dmytro Kharkov
Yesterday

Meme stocks vs. memecoins: Same viral frenzy, different endgames

Anastasiia Chabaniuk
12.11.2026

Better than Bitcoin? The coins that tried to dethrone the king

Hanna Syniavska
5 min ago

Elasticity often misused in oil market, Anas Alhajji notes

Oksana Koneva
9 min ago

Price for ripple:native under $1 is 'pathetic', Mason Versluis states

Alena Volkova
30 min ago

Jim Marous: Daily transaction data reveals customer spending with competitors

Pavlo Kot
34 min ago

Nvidia may not maintain industry leadership without Jensen, Steve Hou notes

Oksana Koneva
1 hour ago

Gold volatility surpasses S&P 500 by 2.1 times, Mike McGlone notes

Top News

Sholanke Dele
4 hours ago

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Darina Pashchenko
4 hours ago

Bitcoin plunges below $67,000 as crypto liquidations reach $656 million

Bitcoin plunges below $67,000 as crypto liquidations reach $656 million

Pavlo Kot
7 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Ivan Andriyenko
22 hours ago

Bessent warns Fed against aggressive rate hikes amid energy shock

Bessent warns Fed against aggressive rate hikes amid energy shock

Igor Krasulya
23 hours ago

Oil prices diverge as U.S. inventories rise and Iran tensions persist

Oil prices diverge as U.S. inventories rise and Iran tensions persist

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

AMD stock faces profit-taking risk as AI momentum builds

Olga Shendetskaya
Now

Eurozone economy outperforms expectations, strengthening case for ECB rate hike

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength threatens a drop to 1.1000

Mykhailo Ihnatenko
Now

Ethereum drops below $2,000: Can ETH recover amid $1.64 billion in crypto liquidations?

Pavlo Kot
Now

Indian authorities raid CoinDCX and Delta Exchange over suspicious crypto transactions

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.